MDG1 Stock Overview
A biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Medigene AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.54 |
| 52 Week High | €5.80 |
| 52 Week Low | €1.42 |
| Beta | 0.91 |
| 11 Month Change | -16.25% |
| 3 Month Change | -31.73% |
| 1 Year Change | -50.61% |
| 33 Year Change | -76.73% |
| 5 Year Change | -86.06% |
| Change since IPO | -99.72% |
Recent News & Updates
Recent updates
Here's Why We're Watching Medigene's (ETR:MDG1) Cash Burn Situation
Jan 03
The Strong Earnings Posted By Medigene (ETR:MDG1) Are A Good Indication Of The Strength Of The Business
Aug 12Medigene AG (ETR:MDG1) Analysts Just Trimmed Their Revenue Forecasts By 41%
Aug 10We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely
Mar 24Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation
Nov 29This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medigene AG's (ETR:MDG1) CEO
Jun 17We're Keeping An Eye On Medigene's (ETR:MDG1) Cash Burn Rate
Mar 29How Much Did Medigene's(ETR:MDG1) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 16How Much Is Medigene's (ETR:MDG1) CEO Getting Paid?
Dec 23Shareholder Returns
| MDG1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.6% | -0.7% | -0.02% |
| 1Y | -50.6% | -17.2% | 8.2% |
Return vs Industry: MDG1 underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: MDG1 underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| MDG1 volatility | |
|---|---|
| MDG1 Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MDG1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MDG1's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 87 | Selwyn Ho | www.medigene.com |
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Medigene AG Fundamentals Summary
| MDG1 fundamental statistics | |
|---|---|
| Market cap | €22.64m |
| Earnings (TTM) | -€15.93m |
| Revenue (TTM) | €7.45m |
3.0x
P/S Ratio-1.4x
P/E RatioIs MDG1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDG1 income statement (TTM) | |
|---|---|
| Revenue | €7.45m |
| Cost of Revenue | €1.49m |
| Gross Profit | €5.95m |
| Other Expenses | €21.89m |
| Earnings | -€15.93m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | 79.94% |
| Net Profit Margin | -213.98% |
| Debt/Equity Ratio | 0% |
How did MDG1 perform over the long term?
See historical performance and comparison